KSX01-TCRT Injection Project in Solid Tumors
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
TCR-T Cells|Refractory Solid Tumors|Relapsed Solid Tumors
DRUG: KSX01-TCRT injection
Subject safety, Number of participants with treatment-related adverse events assessed by CTCAE v4.0., about 2 years|tumor efficacy, Changes in overall tumor diameter., about 2 years
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.